Contour Health Review: What Its Compounded GLP-1 Documentation Establishes—and What It Does Not

Contour Health’s most important evidence distinction is one its own weight-loss page acknowledges: the clinical trials it references concern FDA-approved branded medicines, not the compounded injections it offers. That distinction matters more than a prominent weight-loss percentage. A provider can describe a consultation process, identify a dispensing pharmacy and publish prices without establishing how its particular preparations perform. This review separates those documentary claims from clinical evidence, rather than treating a familiar ingredient name as proof of a particular service’s results.

The public documentation consulted October 19, 2026 describes a telehealth business offering compounded injectable semaglutide and tirzepatide, free consultations, included follow-up and weight-loss medication purchased by the vial rather than through a subscription. Those are useful operational details, but some pages disagree about starting prices, vial duration and age eligibility. Licensure and pharmacy-quality statements remain provider claims, not independently verified findings. For a broader framework, our guide to what public provider documents can prove explains why a documented offering and a demonstrated clinical outcome are different findings.

At a glance

Documented offering: Contour Health advertises compounded semaglutide and tirzepatide as weekly injections for weight management; prescriptions remain subject to a clinician’s assessment.
Sources: [9] [7]
Pharmacy relationship: The company says Strive Pharmacy compounds and fills prescriptions. Contour Health describes itself as a facilitator, not a pharmacy or medication manufacturer.
Sources: [8] [6]
Unresolved starting prices: The weight-loss table lists compounded semaglutide from $30 per week and tirzepatide from $50 per week, while the same page’s calculator lists semaglutide from $25 per week. Prices depend on dose and medication is sold by the vial.
Sources: [9]
Weight-loss payment model: Weight-loss treatment is advertised as pay-per-vial, without a subscription, membership or automatic refill. Consultation, provider time, check-ins and shipping are advertised as included.
Sources: [8]
Clinical evidence boundary: Contour Health acknowledges that its cited trial results concern FDA-approved branded drugs. FDA does not approve compounded preparations or review them before marketing for safety, effectiveness and quality.
Sources: [9] [1]

Start with the product, not the trial headline

Contour Health’s weight-management offering is compounded semaglutide or compounded tirzepatide, described as once-weekly injections. Its broader catalog includes NAD+, sermorelin and hair-loss treatments using finasteride and minoxidil, with prescribing based on individual assessment. These are distinct offerings, not interchangeable evidence categories. The central question for this review is what supports the actual compounded injectable product a patient would receive—not whether an ingredient with the same name has appeared in a successful branded-drug trial.

The company explicitly states that compounded medications are not FDA approved and that FDA does not review them for safety or effectiveness. FDA’s guidance adds that these preparations do not undergo its premarket quality review. That does not, by itself, prove clinical inequivalence or establish that a particular provider is good or bad. It does mean that FDA approval of a specific branded product cannot be transferred to Contour Health, Strive Pharmacy or a compounded prescription.

FDA recommends compounded drugs when a patient’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That is a useful consultation topic rather than a reason to assume every applicant needs compounding. Our explanation of approved medicines and compounded preparations develops this distinction. The reviewed documentation does not establish provider-specific clinical outcomes for Contour Health’s preparations; its description of individualized care should not be mistaken for such evidence.

What each kind of documentation can establish
Documentation	What it supports	What it does not establish
Contour Health service pages	Advertised consultations, products and follow-up	Measured patient outcomes
Named pharmacy relationship	Who the company says compounds and fills prescriptions	Independent verification of pharmacy claims
Branded-drug clinical trials	Results for the studied products and populations	Results for Contour Health’s compounded preparations
Published starting prices	Advertised entry points with conditions	A universal total price per vial
FDA compounding guidance	General regulatory and safety context	A provider-specific inspection or endorsement

Sources: [7] [9] [8] [1]

Who runs the service, and who supplies the medicine?

The terms identify Desert Contour LLC, doing business as Contour Health, as the website’s owner and operator. They also say Contour Health is not a pharmacy or prescription-fulfillment warehouse: it connects patients with pharmacies that dispense and deliver medication. The homepage names Strive Pharmacy as the business that compounds and fills prescriptions and says Contour Health does not manufacture medication. Those separate responsibilities matter when asking who can answer a prescribing question versus a preparation or delivery question.

The weight-loss page identifies Melissa Musso, NP, as leading clinical care and Dr. Laarni Gonzales-Naval as medical director. It says board-certified nurse practitioners handle dosing and check-ins. These are the company’s descriptions of its clinical team; this review did not independently verify credentials or licenses. A nurse practitioner should not be described as a physician simply because the service is clinician-led, and a medical director’s presence does not mean every consultation is conducted by that physician.

Contour Health describes Strive as a U.S. 503A compounding pharmacy licensed and inspected by its state pharmacy board. Its pages also attribute NABP and PCAB accreditations and LegitScript certification to the pharmacy partner, and state that injectables are compounded under United States Pharmacopeia sterile-compounding standards. These are meaningful claims to identify, but they were not independently checked here. Neither accreditation language nor a named pharmacy substitutes for evidence about the effectiveness of a particular dispensed preparation.

Sources: [6] [9] [8] [7]

The consultation provides a decision point, not guaranteed access

The first consultation is described as a Zoom video visit with a licensed provider who reviews health history, discusses goals and determines whether prescribing is appropriate. Patients need an internet-connected smartphone, tablet or computer with a camera, microphone and Zoom. The terms require an informed-consent agreement before telehealth services. Together, these details describe a real-time evaluation process rather than a promise that completing an online purchase automatically produces a prescription.

The FAQ says there is no required BMI to begin the process and that no laboratory work is required before treatment starts. The first statement concerns access to assessment, not proof that medication is appropriate for everyone. The FAQ also says GLP-1 treatment is generally not recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those who are pregnant or breastfeeding. It says the provider reviews the patient’s full history before prescribing. NIDDK describes medication selection as involving health conditions, other medicines, benefits, adverse effects and cost. A useful consultation therefore asks what information the clinician will use for the individual decision and whether anything beyond the website’s standard intake is needed.

Contour Health claims availability in 46 states, excluding Michigan, Mississippi, Kentucky and Arkansas; this review did not verify those licensing statements independently. Its age rules are inconsistent: the FAQ advertises access from age 15, with case-by-case assessment and parental consent and oversight below 18, while the terms restrict services to people who have reached their jurisdiction’s legal age of majority. For this adult-focused review, the practical lesson is to confirm applicable eligibility rather than treating either page as resolving the conflict.

Sources: [7] [6] [2]

Follow-up is more specific than a promise of ongoing support

The FAQ promises that patients will be matched with a provider licensed in their state and remain with that provider throughout care. It describes check-ins at least every two weeks by text, with the option to reach out more frequently or request a video follow-up. This is more informative than simply advertising access to support. It identifies a stated contact cadence and communication method, although the documentation does not establish how consistently that service performs in practice.

Provider responses are described as typically arriving within about 24 hours Monday through Friday; the FAQ says providers take weekends off. Direct provider texts go to (435) 705-5696. Technical or logistical questions can go by call or text to office staff at (435) 414-0360. The site directs urgent concerns to the clinic, but that statement should not be read as evidence of continuous clinical coverage or a guaranteed emergency response.

NIDDK emphasizes that follow-up concerns tolerance and response, not just payment renewal. Contour Health’s stated continuity and two-week check-ins create opportunities for that discussion, but they do not document the content or results of every encounter. Its educational material is explicitly general information, not a substitute for medical advice. Our guide to clinical follow-up beyond renewal notices offers a useful framework for asking what monitoring and escalation responsibilities actually belong to the care team.

Sources: [7] [5] [2]

Starting prices do not resolve the first vial’s cost

Contour Health publishes prices, but they do not form a single consistent quote. The homepage advertises weight loss from $120 per month at the starting dose, with price determined by dose. The weight-loss table lists compounded injectable semaglutide from $30 per week and compounded injectable tirzepatide from $50 per week. A calculator on that same page instead lists semaglutide from $25 per week. The documentation does not resolve which semaglutide starting figure would apply to a particular patient.

Supply descriptions also vary. A table note says medication is sold in two-month vials, while another passage says a vial typically lasts 6–14 weeks depending on dose. Neither statement supplies a universal vial volume or total purchase price. Weekly advertising figures should not be treated as weekly billing, and a monthly comparison should not silently become a four-week period. The page says the exact dose and cost are confirmed at the free consultation before any payment.

The homepage says medication pricing includes the consultation, provider time, individualized dosing, check-ins and shipping. However, the reviewed material also contains general terms allowing shipping and handling charges disclosed at purchase, plus applicable taxes, without clarifying when those provisions apply. The useful next document is therefore an itemized, patient-specific quote showing the compounded product, vial presentation, expected duration, full charge and included services—not an extrapolation from whichever starting figure looks lowest.

Sources: [8] [9] [6]

Weight-loss ordering and subscription terms are not the same thing

For weight loss, Contour Health advertises payment by the vial when the patient chooses to reorder, with no subscription, membership or automatic refill. The FAQ describes a refill conversation: patient and clinician review progress and determine the next vial size, then payment is processed and the order placed. That supports a per-order model, not a recurring monthly membership. It also means an advertised monthly amount does not establish what will actually be collected at the first purchase.

The broader terms discuss certain subscription products with a minimum three-month commitment, automatic billing and at least 30 days’ cancellation notice after that commitment. The FAQ identifies hair loss as a separate quarterly auto-refill program: $148 every three months for daily tablets, advertised as $49 per month, or $189 every three months for topical treatment, advertised as $63 per month. Each charge ships a three-month supply. Those terms should not be imported into the separately advertised weight-loss arrangement.

Hair-loss enrollment requires the first three-month supply; afterward, cancellation requires emailing reception@contourhealthrx.com at least 30 days before the next quarterly charge, with no cancellation fee. Separately, the general terms say all products purchased through Contour Health are non-refundable. Freedom to stop future weight-loss orders therefore does not establish a right to reverse an existing purchase. The consulted documentation does not clarify refund exceptions for damaged shipments, ordering mistakes or other fulfillment problems.

Sources: [8] [7] [6]

Delivery claims need a separate safety and responsibility check

The FAQ says prescribed medication ships directly from the pharmacy partner to the patient’s home, typically arriving within three to five business days once prescribed. This is an advertised arrival estimate, not merely a dispatch estimate, but it is not a guaranteed total time from booking. The documentation does not separately specify clinical-review, preparation and dispatch intervals. The homepage says injectables ship with needed supplies, while the terms warn that partner-pharmacy prescriptions may lack child-resistant packaging.

FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. That guidance matters independently of any advertised delivery window. FDA also reports measurement and administration errors with compounded medicines, some associated with hospitalization. Those reports do not establish Contour Health’s event rate. Readers should clarify their actual prescription and instructions with the prescriber or pharmacist, rather than calculating an injection amount from an article or an advertised vial duration.

The terms also contain a pharmacy-channel exception: if a prescription is unavailable through partner pharmacies, Contour Health says it will send it to a pharmacy selected by the patient, who must arrange pickup or delivery and pay for the medication. That is materially different from the standard advertised included-shipping arrangement. Before authorizing a purchase, establish which pharmacy will fill it, which charges apply and whom to contact about supplies, delivery conditions or a problem with the received product.

Sources: [7] [8] [6] [1]

Research and payment documentation answer different questions

Contour Health’s acknowledgment that its displayed trial findings concern approved branded medicines is an important boundary. STEP 1 and SURMOUNT-1 were randomized trials, not evaluations of this telehealth company or its compounded products. Their findings do not establish results for different preparations, routes or an individual patient, and comparisons across the two trials are not randomized head-to-head evidence. Our guide explains why a clinical trial is not a company performance report. This review does not assign Contour Health an efficacy ranking.

Financial documentation has a different role. The terms say Contour Health does not participate in Medicare, Medicaid or private insurance plans and makes patients responsible for services and products. It accepts HSA/FSA-linked credit or debit cards but does not guarantee that an administrator will recognize the purchase as an eligible expense. The company offers an itemized receipt, and a provider may supply a letter of medical necessity on request. Card acceptance therefore should not be mistaken for confirmed reimbursement.

The remaining gaps are practical as well as scientific: unresolved starting prices and vial durations, unverified licensing and accreditation claims, unclear shipment-refund exceptions and no documented Spanish-language or interpretation availability in the reviewed material. These gaps do not prove that services or accommodations are absent. They identify questions public documentation cannot answer. A useful consultation should produce a clearer product-specific and patient-specific record without relying on branded-drug trial results to fill operational or clinical uncertainties.

Sources: [9] [6] [7] [3] [4]

Questions & answers

Is Contour Health itself the compounding pharmacy?

No. Its terms describe it as a facilitator, not a pharmacy or fulfillment warehouse. The homepage says Strive Pharmacy compounds and fills prescriptions and that Contour Health does not manufacture medication. These are documented descriptions of the arrangement, not independently verified licensing findings. Ask which pharmacy location will fill your specific prescription and which contact handles product questions.

Sources: [6] [8]

What will the first semaglutide purchase cost?

The public pages do not provide one dependable universal total. The weight-loss table says compounded injectable semaglutide starts at $30 per week, while its calculator says $25 per week; the homepage advertises weight loss from $120 per month at the starting dose. Medication is sold by the vial, with dose-dependent pricing. Contour Health says the free consultation confirms the exact cost before payment.

Sources: [9] [8]

Does weight-loss treatment renew automatically?

The weight-loss advertising says no: purchases are by the vial, without a subscription, membership or automatic refill. The FAQ says patients and providers decide on the next vial before payment and ordering. Hair-loss treatment is different and uses quarterly automatic refills. General subscription provisions should therefore be distinguished from the documented weight-loss model, while the separate non-refundable-products term still matters.

Sources: [8] [7] [6]

How often can I expect contact with my provider?

The FAQ promises text check-ins at least every two weeks, permits more frequent outreach and allows requested video follow-ups. Typical provider responses are described as about 24 hours on weekdays, not continuous weekend coverage. The published provider text line is (435) 705-5696; office staff handle technical and logistical issues at (435) 414-0360. These are advertised service expectations, not measured response-time findings.

Sources: [7]

Do the cited drug trials prove Contour Health’s results?

No. Contour Health itself says its trial results refer to FDA-approved branded medications. STEP 1 and SURMOUNT-1 did not test this provider’s service or compounded preparations. Their findings cannot establish an individual result or a provider-specific efficacy ranking. Compounded preparations lack FDA approval, but that fact alone also does not demonstrate clinical inequivalence. These are separate evidence questions, not opposite shortcuts to a verdict.

Sources: [9] [3] [4] [1]

Can I use insurance or an HSA/FSA card?

The terms say Contour Health does not participate in Medicare, Medicaid or private insurance plans, leaving patients financially responsible. HSA/FSA-linked cards are accepted, but administrator approval of the expense is not guaranteed. An itemized receipt is available, and a provider may supply a medical-necessity letter on request. Confirm expense eligibility with the account administrator rather than interpreting a successful card payment as approval.

Sources: [6]

Our assessment

Contour Health documents a recognizable care pathway: a video consultation, individualized prescribing, a named compounding pharmacy, regular text follow-up and patient-initiated vial reorders. Its explicit separation of branded-drug trial findings from compounded offerings is a useful disclosure. The evidence is less settled on commercial specifics: conflicting semaglutide starting figures, inconsistent vial-duration descriptions and general terms that need to be reconciled with program-specific promises. Public claims about licensing and pharmacy credentials were not independently verified, and the reviewed material does not establish clinical outcomes for its preparations. A reasonable next step is to request a written product-specific quote, pharmacy identification, follow-up expectations and fulfillment-problem policy before paying. The service is documented; its compounded-product results should not be presumed from research on other products.

Visit Contour Health’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Contour Health Review: What Its Compounded GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the trial headline

02Who runs the service, and who supplies the medicine?

03The consultation provides a decision point, not guaranteed access

04Follow-up is more specific than a promise of ongoing support

05Starting prices do not resolve the first vial’s cost

06Weight-loss ordering and subscription terms are not the same thing

07Delivery claims need a separate safety and responsibility check

08Research and payment documentation answer different questions